Endocrine side effects in patients treated with immune checkpoint inhibitors: a narrative review
NI Profili, R Castelli, A Gidaro, A Merella… - Journal of Clinical …, 2023 - mdpi.com
Checkpoint inhibitors are monoclonal antibodies that elicit an anti-tumor response by
stimulating immune system. Their use has improved the treatment of different types of cancer …
stimulating immune system. Their use has improved the treatment of different types of cancer …
Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
S Zhang, Y Cheng - Frontiers in Oncology, 2023 - frontiersin.org
Small-cell lung cancer (SCLC) is a fatal subtype of lung cancer characterized by high
aggressiveness, poor prognosis, and limited treatment options. For the first time in more than …
aggressiveness, poor prognosis, and limited treatment options. For the first time in more than …
A retrospective real‐world experience of immunotherapy in patients with extensive stage small‐cell lung cancer
G Qiu, F Wang, X Xie, T Liu, C Zeng, Z Chen… - Cancer …, 2023 - Wiley Online Library
Background The treatment of extensive stage small‐cell lung cancer (ES‐SCLC) has only
made modest progress in the past decade, with two immune checkpoint inhibitors (ICIs) …
made modest progress in the past decade, with two immune checkpoint inhibitors (ICIs) …
Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter …
J Xie, M Chen, H Han, K Xu, G Qiu, X Lin… - Thoracic …, 2023 - Wiley Online Library
Objectives Our research aimed to evaluate the effectiveness of first‐line immune checkpoint
inhibitors (ICIs) with etoposide and platinum (EP) for extensive‐stage small cell lung cancer …
inhibitors (ICIs) with etoposide and platinum (EP) for extensive‐stage small cell lung cancer …
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis
L Bonanno, L Calvetti, A Dal Maso, A Pavan… - Frontiers in …, 2024 - frontiersin.org
Background Recent clinical trials demonstrated longer survival in extended small cell lung
cancer (SCLC) patients treated with immunotherapy in addition to chemotherapy. However …
cancer (SCLC) patients treated with immunotherapy in addition to chemotherapy. However …
Efficacy and safety of immunotherapy combined with chemotherapy in patients with ES‐SCLC: A systematic review and network meta‐analysis of RCTs and RWSs
R Kang, J Ma, B Ai, J Liu, Z Zheng, J Yu - Thoracic Cancer, 2024 - Wiley Online Library
Objectives To evaluate the efficacy and safety of programmed cell death 1 (PD‐
1)/programmed cell death ligand 1 (PD‐L1) inhibitors in the treatment of extensive‐stage …
1)/programmed cell death ligand 1 (PD‐L1) inhibitors in the treatment of extensive‐stage …
[HTML][HTML] Real-world comparison of chemo-immunotherapy and chemotherapy alone in the treatment of extensive-stage small-cell lung cancer
D Lamy, P Mouillot, A Mariet, R Barnestein… - … Medicine and Research, 2024 - Elsevier
Introduction Small cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma
responsible for 200,000 deaths per year worldwide. Platinum-etoposide-based …
responsible for 200,000 deaths per year worldwide. Platinum-etoposide-based …
Durvalumab plus platinum-etoposide chemotherapy for extensive-stage small cell lung cancer: a retrospective real-world study
K Misawa, K Watanabe, M Seike… - … Lung Cancer Research, 2024 - pmc.ncbi.nlm.nih.gov
Background Immune checkpoint inhibitor plus platinum-etoposide (PE) improved overall
survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC). While the …
survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC). While the …
Prognostic Nomogram for Predicting Survival in Asian Patients With Small‐Cell Lung Cancer: A Comprehensive Population‐Based Study and External Verification
Y Xia, J Qu, Y Wang, Y Zhu, J Zhou… - The Clinical Respiratory …, 2024 - Wiley Online Library
Background The incidence of small cell lung cancer (SCLC) among Asian patients is on the
rise. Nevertheless, there remains a deficiency in precise prognostic models tailored to the …
rise. Nevertheless, there remains a deficiency in precise prognostic models tailored to the …
A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung …
F Musicco, C Fulgenzio, AL Malfa… - Journal of Oncology …, 2024 - journals.sagepub.com
Introduction The aim of this study was to analyze real-life data from a cohort of adult patients
receiving atezolizumab in combination with carboplatin and etoposide for first-line treatment …
receiving atezolizumab in combination with carboplatin and etoposide for first-line treatment …